Chronic obstructive pulmonary disease
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with COPD, stage I-IV by the GOLD airflow limitation classification 2) Patients who are deemed stable by the physician and can be adequately evaluated by cardiopulmonary exercise testing (Stable as defined here is defined as no sudden worsening of symptoms such as cough, sputum, or dyspnea on exertion in COPD patients within 1 month retrospectively from the start of the study, and when the drug dose and drug content are constant.) 3) Patients who have given their written, informed consent
Exclusion criteria
Exclusion criteria: 1) Patients with malignant tumors (patients with no recurrence 5 years after treatment are not excluded from the trial) 2) Patients with active infections 3) Patients with severe cardiac disease 4) Patients with bronchial asthma 5) Patients undergoing respiratory rehabilitation 6) Patients requiring FiO2 higher than 24% during cardiopulmonary exercise testing 7) Patients at obvious high risk for pneumothorax, such as a history of repeated pneumothorax, huge bullae,etc. 8) Other patients deemed inappropriate by the physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlations between the degree of upper airway obstruction and one-second forced expiratory volume-related variables (%FEV1, FEV1, FEV1/FVC, PEF, PEF (V'25 V'50)) | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlations between the degree of upper airway obstruction and (1) resting pulmonary function variables other than those in the previous section, (2) cardiopulmonary exercise testing variables, (3) impedance values on oscillometry, (4) maximum inspiratory and expiratory muscle strength, and (5) subjective symptoms (CAT scores) Correlations between the degree of central airway obstruction in the mediastinum and (1) resting pulmonary function variables, (2) cardiopulmonary exercise testing variables, (3) impedance values on oscillometry, (4) maximum inspiratory and expiratory muscle strength, and (5) subjective symptoms (CAT scores) | — |
Countries
Japan
Contacts
NHO Osaka Toneyama Medical Center Laboratory of Respiratory Science, Division of Clinical Research